The University of Texas MD Anderson Cancer Center and Xilis today announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphere™ technology in support of preclinical research to accelerate the development of novel cancer therapies.
[The University of Texas MD Anderson Cancer Center]